Logo

Biomedino Sues Waters, GE Healthcare, Agilent Over Drug Immunoassay Technology

Jan 13, 2005

NEW YORK, Jan. 13 (GenomeWeb News) - Seattle-based Biomedino has sued Waters, GE Healthcare, and Agilent Technologies for allegedly infringing its immunoassay technology for measuring psychoactive drugs, GenomeWeb News has learned.

 

Biomedino filed suit on Jan. 7 with the US District Court for the Western District of Washington, Seattledivision. The company claims that Waters, GE Healthcare, and Agilent infringe its USpatent No. 6,602,502, entitled "Methods and devices for removing species."

 

The patent, granted to Meir Strahilevitz, the sole inventor, in August 2003 and licensed to Biomedino, covers immunoassays of psychoactive drugs and treatment methods, based on the antigenic properties of protein conjugates of these drugs.

 

Biomedino said in its complaint that several chromatography-based separations systems made by the three plaintiffs infringe its patents. The company is seeking damages from all three "which in no event can be less than a reasonable royalty."

 

An Agilent spokesperson said the company has not yet been served with the suit. Officials from GE Healthcare and Waters did not immediately return a telephone call seeking comment.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.